Serum Uric Acid and C-reactive Protein in Patients with Metastatic Colorectal Carcinoma During Combination Therapy with High-dose Folinic Acid
New spectrum of side effects has emerged with the introduction of targeted therapies, including changes in parameters determining cardiovascular risk. Among other laboratory parameters, hyperuricemia and elevated Creactive protein (CRP) are associated with increased risk of cardiovascular disease. T...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
De Gruyter
2012-02-01
|
| Series: | Pteridines |
| Subjects: | |
| Online Access: | https://doi.org/10.1515/pteridines.2012.23.1.8 |
| _version_ | 1819102118143852544 |
|---|---|
| author | Melichar Bohuslav Hyšpler Radomír Kalábová Hana Holecková Petra Študentová Hana |
| author_facet | Melichar Bohuslav Hyšpler Radomír Kalábová Hana Holecková Petra Študentová Hana |
| author_sort | Melichar Bohuslav |
| collection | DOAJ |
| description | New spectrum of side effects has emerged with the introduction of targeted therapies, including changes in parameters determining cardiovascular risk. Among other laboratory parameters, hyperuricemia and elevated Creactive protein (CRP) are associated with increased risk of cardiovascular disease. The aim of the present study was to investigate the changes of serum uric acid and CRP during the therapy with cetuximab, combined with 5- fluorouracil and high-dose folinic acid, in patients with metastatic colorectal carcinoma and the association of these changes with the outcome of the therapy. CRP and uric acid were determined using particle-enhanced immunoturbidimetric assay and uricase method, respectively. Measurements before and during the treatment were compared by Wilcoxon signed rank test, and comparison between survivors and non-survivors was performed by Mann-Whitney U test. Compared to baseline (pre-treatment) concentrations, serum uric acid was decreased significantly throughout the course of the combination treatment with irinotecan, 5-fluorouracil, highdose folinic acid and cetuximab. The decrease was evident early in the course of treatment. Serum CRP was also decreased significantly throughout the most of the course of therapy. The significant decrease of serum uric acid and CRP was evident already one week after the start of treatment. Serum CRP was significantly lower in patients who survived 12 months, but no difference of uric acid concentrations between survivors and non-survivors was found. A marked decrease of serum uric acid was observed during the combination therapy. High CRP was associated with poor prognosis, but no association between uric acid and prognosis was noted. |
| first_indexed | 2024-12-22T01:29:28Z |
| format | Article |
| id | doaj.art-c4c857eeaf3d4bfbb582f6b2ecc5654a |
| institution | Directory Open Access Journal |
| issn | 0933-4807 2195-4720 |
| language | English |
| last_indexed | 2024-12-22T01:29:28Z |
| publishDate | 2012-02-01 |
| publisher | De Gruyter |
| record_format | Article |
| series | Pteridines |
| spelling | doaj.art-c4c857eeaf3d4bfbb582f6b2ecc5654a2022-12-21T18:43:31ZengDe GruyterPteridines0933-48072195-47202012-02-0123181310.1515/pteridines.2012.23.1.8Serum Uric Acid and C-reactive Protein in Patients with Metastatic Colorectal Carcinoma During Combination Therapy with High-dose Folinic AcidMelichar Bohuslav0Hyšpler Radomír1Kalábová Hana2Holecková Petra3Študentová Hana4Professor and Head, Department of Oncology, Palacký University, Medical School & Teaching Hospital, I.P. Pavlova 6, 775 20 Olomouc, Czech Republic phone: +420-588444288; fax: +420-588442522Departments of Gerontology & Metabolic Care, Charles University Medical School and Teaching Hospital, Hradec Králové, Czech RepublicDepartment of Oncology, Palacký University Medical School and Teaching Hospital, Olomouc,Czech RepublicInstitute of Experimental Neurosurgery, Charles University Medical School and Teaching Hospital, Hradec Králové, Czech RepublicDepartment of Oncology, Palacký University Medical School and Teaching Hospital, Olomouc,Czech RepublicNew spectrum of side effects has emerged with the introduction of targeted therapies, including changes in parameters determining cardiovascular risk. Among other laboratory parameters, hyperuricemia and elevated Creactive protein (CRP) are associated with increased risk of cardiovascular disease. The aim of the present study was to investigate the changes of serum uric acid and CRP during the therapy with cetuximab, combined with 5- fluorouracil and high-dose folinic acid, in patients with metastatic colorectal carcinoma and the association of these changes with the outcome of the therapy. CRP and uric acid were determined using particle-enhanced immunoturbidimetric assay and uricase method, respectively. Measurements before and during the treatment were compared by Wilcoxon signed rank test, and comparison between survivors and non-survivors was performed by Mann-Whitney U test. Compared to baseline (pre-treatment) concentrations, serum uric acid was decreased significantly throughout the course of the combination treatment with irinotecan, 5-fluorouracil, highdose folinic acid and cetuximab. The decrease was evident early in the course of treatment. Serum CRP was also decreased significantly throughout the most of the course of therapy. The significant decrease of serum uric acid and CRP was evident already one week after the start of treatment. Serum CRP was significantly lower in patients who survived 12 months, but no difference of uric acid concentrations between survivors and non-survivors was found. A marked decrease of serum uric acid was observed during the combination therapy. High CRP was associated with poor prognosis, but no association between uric acid and prognosis was noted.https://doi.org/10.1515/pteridines.2012.23.1.8c-reactive proteincolorectal carcinomacetuximaburic acid |
| spellingShingle | Melichar Bohuslav Hyšpler Radomír Kalábová Hana Holecková Petra Študentová Hana Serum Uric Acid and C-reactive Protein in Patients with Metastatic Colorectal Carcinoma During Combination Therapy with High-dose Folinic Acid Pteridines c-reactive protein colorectal carcinoma cetuximab uric acid |
| title | Serum Uric Acid and C-reactive Protein in Patients with Metastatic Colorectal Carcinoma During Combination Therapy with High-dose Folinic Acid |
| title_full | Serum Uric Acid and C-reactive Protein in Patients with Metastatic Colorectal Carcinoma During Combination Therapy with High-dose Folinic Acid |
| title_fullStr | Serum Uric Acid and C-reactive Protein in Patients with Metastatic Colorectal Carcinoma During Combination Therapy with High-dose Folinic Acid |
| title_full_unstemmed | Serum Uric Acid and C-reactive Protein in Patients with Metastatic Colorectal Carcinoma During Combination Therapy with High-dose Folinic Acid |
| title_short | Serum Uric Acid and C-reactive Protein in Patients with Metastatic Colorectal Carcinoma During Combination Therapy with High-dose Folinic Acid |
| title_sort | serum uric acid and c reactive protein in patients with metastatic colorectal carcinoma during combination therapy with high dose folinic acid |
| topic | c-reactive protein colorectal carcinoma cetuximab uric acid |
| url | https://doi.org/10.1515/pteridines.2012.23.1.8 |
| work_keys_str_mv | AT melicharbohuslav serumuricacidandcreactiveproteininpatientswithmetastaticcolorectalcarcinomaduringcombinationtherapywithhighdosefolinicacid AT hysplerradomir serumuricacidandcreactiveproteininpatientswithmetastaticcolorectalcarcinomaduringcombinationtherapywithhighdosefolinicacid AT kalabovahana serumuricacidandcreactiveproteininpatientswithmetastaticcolorectalcarcinomaduringcombinationtherapywithhighdosefolinicacid AT holeckovapetra serumuricacidandcreactiveproteininpatientswithmetastaticcolorectalcarcinomaduringcombinationtherapywithhighdosefolinicacid AT studentovahana serumuricacidandcreactiveproteininpatientswithmetastaticcolorectalcarcinomaduringcombinationtherapywithhighdosefolinicacid |